Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales, driven by Medicare coverage, low market penetration, and European launch, making MDGL stock a STRONG BUY.
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25.
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
